Finerenone shows promise for kidney protection in type 1 diabetes amid cautious optimism

Recent trial data suggest finerenone could become one of the few drugs to address the long-standing treatment gap in kidney protection for type 1 diabetes, prompting cautious optimism among clinicians and a review of current guidelines. Finerenone, a non-steroidal mineralocorticoid…













